Assignee
SURROZEN OPERATING INC
US·7 granted patents·14 pending applications·8 citations·filing 2018–2025
Top patents by PatentIndex Score
21 records- 0191US12240876B2Liver-specific Wnt signal enhancing molecules and uses thereofSURROZEN OPERATING INC·Filed 2023·Granted Mar 4, 2025·1 cites·10 claims
- 0286US12006368B2Anti-frizzled antibodies and methods of useSURROZEN OPERATING INC·Filed 2018·Granted Jun 11, 2024·3 cites·8 claims
- 0378US12297278B2Wnt surrogate molecules and uses thereofSURROZEN OPERATING INC·Filed 2023·Granted May 13, 2025·0 cites·5 claims
- 0478US11958891B2Tissue-specific Wnt signal enhancing molecules and uses thereofSURROZEN OPERATING INC·Filed 2018·Granted Apr 16, 2024·2 cites·14 claims
- 0577US11746150B2Anti-LRP5/6 antibodies and methods of useSURROZEN OPERATING INC·Filed 2018·Granted Sep 5, 2023·1 cites·10 claims
- 0675US11773171B2WNT surrogate molecules and uses thereofSURROZEN OPERATING INC·Filed 2018·Granted Oct 3, 2023·1 cites·10 claims
- 0773US2024279303A1Tissue-specific wnt signal enhancing molecules and uses thereofSURROZEN OPERATING INC·Filed 2024·Application pending·0 cites
- 0872US2024368287A1Anti-frizzled antibodies and methods of useSURROZEN OPERATING INC·Filed 2024·Application pending·0 cites
- 0970US2024150458A1Anti-lrp5/6 antibodies and methods of useSURROZEN OPERATING INC·Filed 2023·Application pending·0 cites
- 1069US2025223368A1Wnt surrogate molecules and uses thereofSURROZEN OPERATING INC·Filed 2025·Application pending·0 cites
- 1167US2024262918A1Fc-modified wnt surrogate molecules and uses thereofSURROZEN OPERATING INC·Filed 2023·Application pending·0 cites
- 1266US2025313616A1Modulation of wnt signalling in ocular disordersSURROZEN OPERATING INC·Filed 2025·Application pending·0 cites
- 1362US2025051459A1Wnt-surrogate agents and methods for lacrimal gland regenerationSURROZEN OPERATING INC·Filed 2022·Application pending·0 cites
- 1462US2023295347A1Wnt receptor-specific compound and method relating theretoSURROZEN OPERATING INC·Filed 2022·Application pending·0 cites
- 1559US2025171509A1Liver-specific wnt signal enhancing molecules and uses thereofSURROZEN OPERATING INC·Filed 2025·Application pending·0 cites
- 1658US2024150473A1Modulation of wnt signaling in gastrointestinal disordersSURROZEN OPERATING INC·Filed 2022·Application pending·0 cites
- 1755US2023138045A1Wnt super agonistsSURROZEN OPERATING INC·Filed 2021·Application pending·0 cites
- 1854US2024391991A1Modulation of wnt signalling in pulmonary disordersSURROZEN OPERATING INC·Filed 2022·Application pending·0 cites
- 1951US2022175884A1Modulation of wnt signaling in auditory disordersSURROZEN OPERATING INC·Filed 2020·Application pending·0 cites
- 2048US12466884B2Tissue-specific WNT signal enhancing molecules and usesSURROZEN OPERATING INC·Filed 2019·Granted Nov 11, 2025·0 cites·11 claims
- 2145US2022195053A1Modulation of wnt signaling in gastrointestinal disordersSURROZEN OPERATING INC·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when SURROZEN OPERATING INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →